



Daily 14.VI.2022

Company	LT fundamental recommendation	12M EFV (PLN)	ST market-relative bias	Analyst
BioMaxima	Not rated	37.3	Not rated	Sylwia Jaśkiewicz, CFA Mikołaj Stępień

Event: tests for identification of the Monkeypox genes placed on the market

Yesterday the Company informed that it was granted the right to place 2 tests for identification of the monkeypox virus on the market: genetic test MPXV Real Time PCR LAB-KIT and Monkeypox Ag Rapid Test. They will be available for sale on the domestic market and foreign markets.

Until June 8, there 1,285 cases of monkeypox reported in 28 countries in which this disease has not been endemic. On June 10, the first case of monkey was detected in Poland.

Expected impact: *the information was discounted during yesterday's session.*

The report is not a recommendation within the meaning of Commission Delegated Regulation (EU) 2016/958 of 9 March 2016 supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest.